Comparative Pharmacology
Head-to-head clinical analysis: HERNEXEOS versus LIVTENCITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HERNEXEOS versus LIVTENCITY.
HERNEXEOS vs LIVTENCITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Trastuzumab deruxtecan is a HER2-targeted antibody-drug conjugate (ADC). The antibody binds to HER2 on tumor cells, leading to internalization and intracellular release of the topoisomerase I inhibitor payload (DXd), which causes DNA damage and apoptosis.
LIVTENCITY (maribavir) is an inhibitor of the human cytomegalovirus (CMV) UL97 protein kinase, which is essential for viral DNA replication, encapsidation, and egress of mature virions from the infected cell. By blocking UL97 kinase activity, maribavir inhibits viral replication.
2.5 mg subcutaneously once daily.
200 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life: 12 hours; clinical context: allows twice-daily dosing in most patients; renal impairment prolongs half-life up to 24 hours
Terminal elimination half-life is approximately 20 hours, supporting once-daily dosing for sustained antiviral activity.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other routes
Primarily hepatobiliary excretion; unchanged drug and metabolites eliminated in feces (86%) and urine (14%).
Category C
Category C
Antiviral
Antiviral